ChemDiv and Avineuro Extend Collaboration on Alzheimer's Disease and Schizophrenia
ChemDiv Inc. and Avineuro Pharmaceuticals Inc. have extended the term of their research and development collaboration including formulation, safety and early clinical development studies in areas of neurodegenerative and psychiatric disorders. R&D services will be provided by Chemical Diversity Research Institute, ChemDiv's research subsidiary based in Moscow.
The new agreement provides for research funding of clinical candidate compounds to POC. Avineuro is responsible for further clinical development and commercialization of drug candidates AVN101, AVN211, and additional compounds that may be nominated for development from the ongoing research and discovery under the agreement.
In September, ChemDiv entered into an out-licensing and collaboration agreement with Avineuro to develop multiple compounds for Alzheimer Disease and schizophrenia. Under the agreement, Avineuro obtained exclusive worldwide rights to clinical development candidates AVN101, AVN211, and lead compounds in various stages of pre-clinical development. ChemDiv will provide pre-clinical development services to nominate additional backup leads and candidates for Avineuro.
ChemDiv, Inc. announced that it has earned the successful milestone in its Lead Discovery collaboration with Nerviano Medical Sciences (NMS). In October 2007, ChemDiv and NMS expanded their partnership to discover and develop potential anticancer agents. Under the terms of the collaboration ... more
Oncalis AG (Oncalis), a privately-owned Swiss biotechnology company, and ChemDiv Inc. (ChemDiv), a privately-owned,California-based discovery services company announced that they entered into an exclusive agreement for a license to Oncalis a family of PI3K inhibitors. ONC-201, the first dev ... more
ChemDiv, Inc. and Syndexa Pharmaceuticals Corporation have announced the signing of a collaborative discovery research agreement. Under the terms of the agreement, ChemDiv will discover small molecule ligands for biotargets nominated by Syndexa. Financial terms of the collaboration were not ... more
Avineuro Pharmaceuticals, Inc. discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Founded in August 2008 and headquartered inSan Diego, California, Avineuro is managed by seasoned professionals experienced in drug discovery and development. By ... more